Introduction
Therapeutic cancer vaccines are receiving increasing interest for treatment of various types of cancer, in particular for patients who do not have naturally occurring antitumor immunity, or who do not benefit from immune checkpoint blockade (ICB) therapy. However, identifying appropriate antigens with tumor-restricted expression, high potential for immunogenicity in humans, and high expression in multiple tumor types has remained challenging.
In the early 1990s, the MAGE-1, melanoma antigen-1 (now renamed MAGE-A1), protein was the first cancer antigen discovered to be recognized by cytolytic T lymphocytes in a human melanoma patient (1) . Subsequently, 10 additional MAGE-A family members were identified in various human cancers, all of which have no or low expression in normal human tissues, with the exception of the placenta and non-MHC-presenting germ cells of the testis (2) (3) (4) . Because of this restricted expression, the MAGE-A family represents an ideal immune therapy target. Furthermore, because of this restricted expression it may less subject to tissuespecific immune tolerance, making it easier to generate a robust immune response against this family of antigens. In support of this concept, T lymphocytes specific for both class I and II epitopes of various MAGE-A family members have been identified in patients with cancer (1, (5) (6) (7) (8) (9) (10) .
The attractiveness of the MAGE family for cancer immune therapy has resulted in the initiation of several clinical trials for vaccines targeting a common family member MAGE-A3. This specific isoform was chosen for clinical study because it was thought at the time to have the highest expression compared with other isoforms in various solid tumors (11) . Efforts to target MAGE-A3 have utilized vaccination with a recMAGE-A3 recombinant protein formulation or cellular therapies using CD8 þ T cells engineered to express a high-affinity MAGE-A3-targeted TCR. While the recMAGE-A3 vaccine was capable of inducing clear humoral responses in patients with cancer, the vaccine produced poor CD8 þ T-cell responses and ultimately failed to demonstrate efficacy in a phase III clinical trial of non-small cell lung cancer (12) (13) (14) . In contrast, the MAGE-A3 TCR cellular therapy demonstrated antitumor activity in several patients; however, this therapy exhibited unexpected off-tumor toxicity resulting in several patient deaths in early-stage clinical trials (15) (16) (17) . Thus, development of therapies targeting antigens in the MAGE-A family driving a more robust T-cell response, but exhibiting a better safety profile, is of high priority.
Peptide or DNA vaccination approaches for targeting the MAGE-A family members may represent important tools in this regard (18, 19) . Several peptides targeting various shared MAGE-A epitopes have been tested in a preclinical or clinical setting, and have shown some induction of limited T-cell responses as well as patient-specific clinical responses (7, 20) . However, these peptides are HLA-restricted and accordingly this strategy is limited to a subset of patients. Clinical trials utilizing optimized synthetic DNA with improved electroporation technology have shown clinical responses and promise for targeting infectious disease and virally driven cancers (21, 22) . Synthetic DNA vaccines also have the advantage of encoding entire antigens, instead of individual peptides, to generate a broader HLA response. Another important advantage of this platform is the ability to design consensus immunogens to induce cross-reactive immune responses against similar, conserved strains of viruses (23) . In the cancer setting, this consensus design strategy can be adapted here to help break tolerance against self-antigens (24, 25) .
In this study, we thoroughly examined expression of the MAGE-A family members in The Cancer Genome Atlas (TCGA) and discovered that all MAGE-A isoforms, not just MAGE-A3 as previously thought, are highly expressed in human cancers. In addition, a high proportion of patients, particularly those with melanoma, exhibit simultaneous expression of multiple isoforms within the same tumor sample. We took advantage of the unique genetic relationships within the MAGE-A family of proteins and designed an optimized consensus DNA vaccine capable of target-ing multiple MAGE-A family members simultaneously. We show that this vaccine is effective at inducing a robust immune response against multiple MAGE-A family members, and at reducing tumor burden and driving CD8 þ T cells to tumors in an autochthonous mouse melanoma model. This optimized, cross-reactive MAGE-A immunogen likely has a significant advantage compared with previously designed MAGE-A3-specific immunotherapies.
Materials and Methods

Cell culture and transfection
293T cells were purchased from ATCC and YUMM1.7 cells were a gift from Dr. Ashani Weeraratna at The Wistar Institute (Philadelphia, PA). These cells were maintained in DMEM supplemented with 10% FBS. These cell lines were routinely tested for Mycoplasma contamination, and were maintained at low passage (<20 passages) in cell culture. 293T cells were transfected with the indicated constructs using the GeneJammer transfection reagent according to the manufacturer's guidelines (Agilent). Cells were harvested using RIPA lysis buffer (Cell Signaling Technology) supplemented with EDTA-free protease inhibitor (Roche) for analysis by Western blot analysis, or were harvested using the RNeasy Plus Mini Kit (QIAGEN) for RNA extraction.
DNA plasmids
The synthetic mouse consensus MAGE-A sequence was generated by aligning mouse MAGE-A1, mouse MAGE-A2, mouse MAGE-A3, mouse MAGE-A5, mouse MAGE-A6, and mouse MAGE-A8 amino acid sequences using ClustalX2. The synthetic human MAGE-A consensus #1 sequence was generated by aligning human MAGE-A2, human MAGE-A3, human MAGE-A6, and human MAGE-A12 amino acid sequences using ClustalX2. The synthetic human MAGE-A consensus #2 sequence was generated by aligning human MAGE-A1, human MAGE-A4, and human MAGE-A5 amino acid sequences using ClustalX2. All sequences were RNA and codon optimized, with a Kozak sequence and an IgE leader sequence added at the N terminus. All plasmids were cloned into the modified pVax1 vector by GenScript. The percentage homology between sequences was calculated using Mega6. Comparative models of the defined MAGE-A consensus sequences were built using the MODELLER algorithm (26) , implemented in Discovery Studio (Biovia). Sequences were analyzed using the PONDR algorithm to predict potential intrinsically disordered regions prior to model building (27) .
Western blot analysis
A total of 4%-12% Bis-Tris NuPAGE gels (Thermo Fisher Scientific) and polyvinylidene difluoride membranes (Millipore) were used for Western blot analysis. Odyssey blocking buffer reagents were used for blocking primary and secondary antibody incubations. The following primary antibodies were used: anti-Actin AC-15 (Sigma, 1:1000), anti-MAGE-A (6C1, Santa Cruz Biotechnology, 1: 200), and anti-FLAG (M2, Sigma, 1:500). The following secondary antibodies were used: IRDye 680RD goat anti-mouse and IRDye 800CW goat anti-rabbit (LI-COR Biosciences). The membrane was imaged using the LI-COR Odyssey CLx.
RNA extraction and qPCR
RNA extraction was performed using a QIAGEN RNeasy Plus Mini Kit. RNA was converted to cDNA using the Applied
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Biosystems High Capacity RNA to cDNA kit. qPCR was performed using Power SYBR Green on an ABI 7900 Fast RT PCR machine. Expression levels are expressed in terms of 2 ÀDC t (DC t is compared with the GAPDH control). The following qPCR primers were used for these studies: pan-mouse MAGE: CCACCTCAAA-TAAAGTGTATGGCA (F), ACCAGAAAGTCCACCAAGTCA (R), mouse MAGE-A consensus: GCCACCATGGATTGGACTTG (F), TGGCCATTGTCTCCTGATCG (R), human MAGE-A consensus #1: GTTTGCACACCCCAGAAAGC (F), GGGTGGGTAGCTGATG-TGAG (R), human MAGE-A consensus #2: TGGCAGATCTGGTG-CACTTT (F), TTCACGTCGATGCCGAAGAT (R), and GAPDH: CCTGCACCACCAACTGCTTA (F), AGTGATGGCATGGACTGT-GGT (R).
Mice and immunization
C57Bl/6 and CD-1 outbred mice were acquired from Jackson Laboratories and housed at The Wistar Institute. The Tyr::CreER; Braf Ca/þ ; Pten lox/lox transgenic mice were generated by Drs. Bosenberg and McMahon (University of California, San Francisco, CA) and housed at the University of Pennsylvania (Philadelphia, PA; ref. 28 ). Genotyping of the mice was performed as described previously (29) . For tumor induction, 6-to 8week-old mice were treated topically with a 5 mmol/L 4hydroxytamoxifen (4-HT, Sigma) solution on the flank to initiate tumor formation (28) . For tumor measurements, the following formula was used: volume ¼ a Â b Â c/2, where a ¼ maximum length, b ¼ maximum width, and c ¼ thickness (30) . Mice were euthanized when they achieved the standard body condition score (multiple tumor spots with maximum length of 30 mm). For immunization, mice were injected with 30 mL of DNA (25 mg per mouse) into the tibialis anterior (TA) muscle, followed by electroporation using the CELLECTRA-3P device (Inovio Pharmaceuticals). Mice were delivered two 0.1-Amp electric constant current square-wave pulses for each immunization. The vaccine schedule is indicated in each figure legend. For subcutaneous YUMM1.7 implantation studies, 2 Â 10 5 cells were implanted into the flank of each mouse. For in vivo depletion experiments, mice were given 200 mg of either isotype control antibody (rat IgG2b, anti-keyhole limpet hemocyanin) or CD8 depletion antibody (clone YTS 169.4, BioXCell) intraperitoneally. Tumor volume for subcutaneous tumors was calculated using the formula: volume ¼ (p/6) Â (height) Â (width 2 ). Mice were euthanized when tumor diameters exceeded 1.5 cm. All animal procedures were done under approval from either the Wistar or University of Pennsylvania Institute Animal Care and Use Committee (IACUC) and the NIH (Bethesda, MD).
Splenocyte and tumor-infiltrating lymphocyte isolation
After mice were euthanized, spleens and tumor tissues (if applicable) were collected in RPMI medium supplemented with 10% FBS. Spleens were processed using a stomacher, red blood cells were lysed using ACK lysis buffer (Life Technologies), and the remaining cells were filtered through a 40-mm filter. Tumors were minced using a scalpel, and incubated in a tumor dissociation enzyme mix consisting of: 170 mg/L collagenase I, II and IV (Thermo Fisher Scientific), 12.5 mg/L DNAse I (Roche), 25 mg/L Elastase (Worthington) in 50% RPMI þ 10% FBS and 50% Hyclone L-15 Leibowitz medium (Thermo Fisher Scientific). Tumors were incubated in this mixture with end-over-end mixing for 1 hour at 37 C, and then filtered twice through a 40-mm filter prior to plating for staining.
ELISpot assay
MABTECH Mouse IFNg ELISpot PLUS plates were used for ELISpot analysis. A total of 2 Â 10 5 splenocytes were plated per well and stimulated for 18-24 hours with 5 mg/mL of peptides (15-mer peptides overlapping by 9 amino acids) in RPMI þ 10% FBS. Spots were developed according to the manufacturer's instructions, and quantified using an ImmunoSpot CTL reader. Spot-forming units (SFU) were calculated by subtracting media alone wells from the peptide-stimulated wells. Concanavalin A stimulation was used as a positive control to ensure proper spot development.
Intracellular cytokine staining and flow cytometry
Splenocytes were stimulated in the presence of 5 mg/mL peptide, Protein Transport Inhibitor Cocktail (eBioscience) and FITC a-mouse CD107a (clone 1D4B, Biolegend) for 5-6 hours. Cell stimulation cocktail was used as a positive control for stimulation instead of peptide. Tumor-infiltrating lymphocytes (TIL) were stained directly without stimulation. After stimulation, cells were washed and incubated with LIVE/DEAD violet. Cells were then incubated with surface stain (in 1% FBS in PBS) for 30 minutes at room temperature, followed by fixation and permeabilization (BD Biosciences) for 15 minutes at 4 C. After permeabilization, cells were washed and incubated in intracellular stain (in fixation/permeabilization wash buffer) for 1 hour at 4 C. The following antibodies were used for analysis: PECy5 aCD3 (clone 145-2C11, BD Pharmingen), BV510 aCD4 (clone RM4-5, Bio-Legend), BV605 aTNFa (clone MP6-XT22), PE aT-bet (clone 4B10, BioLegend), APCCy7 aCD8 (clone 53-6.7, BioLegend), AF700 aCD44 (clone IM7, BioLegend), APC aIFNg (clone XMG1.2, BioLegend), FITC aCD45 (30-F11, BioLegend), BV711 aPD-1 (clone 29F.1A12, BioLegend), PECy7 aCD25 (PC61.5, eBioscience), and APC aFoxP3 (clone FJK-16s, eBioscience). All data were collected on an LSR18 flow cytometer (BD Biosciences) and analyzed using FlowJo software (TreeStar). For analysis, media alone control wells were subtracted from peptide-containing wells for antigen-specific immune responses.
Immunofluorescence/IHC staining
Hematoxylin and eosin staining was performed according to standard protocols from tissue that was fixed in 10% neutral-buffered formalin and paraffin-embedded. For immunofluorescence staining, tissues were collected in optimal cutting temperature medium (Tissue-Tek) on dry ice and stored at À80 C. For CD8, CD31, and Ly6G staining, frozen tissue was fixed on slides with 4% paraformaldehyde (in PBS) for 15 minutes at room temperature, and then permeabilized with 0.5% Triton X-100 for 15 minutes at room temperature. The tissue was blocked for 1 hour at room temperature with 2.5% BSA and 5% horse serum in PBS. The Avidin/Biotin Blocking Kit (Vector Laboratories) was also used to reduce background staining. Primary antibody (CD8a-biotin, 53-6.7 Abcam, 1:2,000; CD31, ab124432, 1:800; Ly6G-biotin, RB6-8C5 Abcam, 1:2,000) in 1% horse serum in PBS was incubated overnight at 4 C in a humidified chamber. The next day, the TSA-Biotin kit (Perkin Elmer) was used for signal amplification for the biotinylated primary antibodies, and slides were incubated in secondary antibody (Streptavidin AF488, 1:500, or goat anti-rabbit AF594 1:300) for 30 minutes at room temperature. Slides were mounted with Prolong Gold Antifade with DAPI. Staining of paraffin-embedded tissues was performed by the Wistar Histotechnology Facility. Slides were imaged with a Nikon 80i upright microscope at The Wistar Institue or a Zeiss LSM Confocal microscope at the University of Pennsylvania Cell and Developmental Biology Microscopy Core. Image analysis was performed using Photoshop or Fiji/ImageJ software.
TCGA data analysis
RNA-seq data (RSEM values) from TCGA were downloaded through the GDAC data portal (https://gdac.broadinstitute.org/). All samples marked as matched normal were filtered and included in the normal tissue control group (n ¼ 754). The following human tumor types were analyzed:
We set the threshold for expression to be greater than 2 SDs above the mean for the normal tissue for each MAGE-A isoform.
Statistical analysis
All statistical analysis was done using GraphPad Prism software. All error bars represent the mean AE the SEM. Statistical significance was determined by a two-tailed t test for experiments with only two experimental groups, or a one-way ANOVA followed by Tukey post hoc HSD test for experiments with more than two experimental groups. For tumor growth over time, multiple t tests were performed for each time point. For mouse survival analysis, significance was determined using a Gehan-Brelow-Wilcoxon test.
Results
MAGE-A isoform expression in human tumors
Various MAGE-A family members have shown to be upregulated in many different human cancers at the protein level, including non-small cell lung cancer, melanoma, breast cancer, ovarian cancer, colon cancer, multiple myeloma, hepatocellular carcinoma, and others (3, 31, 32) . However, currently available anti-human MAGE-A antibodies cross-react with many different isoforms, making it difficult to evaluate isoform-specific expression in patient samples (33) . To achieve a more global picture of MAGE-A isoform expression in human cancers, we analyzed human patient RNA-seq data from TCGA. We downloaded normalized RSEM counts through the GDAC data portal for all human tumors and matched normal samples available (https:// gdac.broadinstitute.org/). We used log-transformed data for our analysis. We set the threshold for expression to be greater than 2 SDs above the mean for the normal tissue control group for each isoform individually. We found that, despite the fact that most immune therapies target the MAGE-A3 isoform, the other 10 isoforms are also highly expressed in a variety of human cancers (Fig. 1A) . When examining all human cancer samples available from the GDAC data portal, tumors that express each isoform range from 9.5% (MAGE-A8) to 29.5% (MAGE-A12; Fig. 1B ). Expression of MAGE-A isoforms were particularly high for patients with bladder cancer, esophageal cancer, glioblastoma, head and neck cancer, lung squamous cell carcinoma, rectum adenocarcinoma, skin cutaneous melanoma, testicular germ center tumors, and uterine carcinosarcoma ( Fig. 1A) . Importantly, over 80% of patients with these tumor types show expression of one or more MAGE-A isoforms. We also found that it was common for patients to express multiple MAGE-A isoforms simultaneously (Fig.  1C ). For instance, over half of patients with lung squamous cell carcinoma (LUSC), skin cutaneous melanoma (SKCM) or testicular germ center tumors (TGCT) show expression of more than 5 MAGE-A isoforms simultaneously (Fig. 1C ). This analysis indicates that an immune therapy targeting multiple MAGE-A isoforms, not just MAGE-A3, would likely be beneficial for a large proportion of patients.
MAGE-A vaccine design and expression
The MAGE-A family does exist in lower vertebrates, and the general domain structure of this antigen family is conserved between mouse and human, with an unstructured N-terminal domain and a MAGE homology domain ( Fig. 2A) . However, the sequence is poorly conserved. The mouse and human MAGE-A proteins share between 25.3% (MAGE-A2) to 38.4% (MAGE-A10) identity (calculated using sequence alignment with ClustalX2). Furthermore, the MAGE-A9, MAGE-A11 and MAGE-A12 isoforms have not been identified in mice. We therefore designed separate vaccines for testing in mice and for preclinical development for humans. We generated a synthetic consensus MAGE-A vaccine for proof-of-concept experiments in mice that shares 94.1% identity with MAGE-A1, 95.1% identity with MAGE-A2, 94.5% identity with MAGE-A3, 96.8% identity with MAGE-A5, 91% identity with MAGE-A6, and 94.8% identity with MAGE-A8 ( Fig. 2B and D) . For preclinical development for humans, we generated two consensus MAGE-A vaccines. The human MAGE-A consensus #1 shares 91.4% identity to human MAGE-A2, 92.7% identity to MAGE-A3, 92.4% identity to MAGE-A6, and 92% identity to MAGE-A12. The human MAGE-A consensus #2 shares 84.6% identity to MAGE-A1, 84.6% identity to MAGE-A4, and 86.3% identity to MAGE-A5 ( Fig. 2C , E, and F). These homologies were chosen as they would allow for theoretical T-cell cross-reactivity for the majority of possible MAGE-A T-cell epitopes. All of these vaccines were RNA and codon optimized for efficient translation and include the IgE leader sequence which promotes protein production and secretion.
We next tested for plasmid vaccine expression in vitro. We transfected 293T cells with the mouse consensus MAGE-A vaccine or a GFP-expressing plasmid as a control. Because there are no commercially available antibodies that recognize mouse MAGE-A isoforms, we probed for expression using qPCR. We detected robust expression of the consensus mouse MAGE-A vaccine in 293T cells in vitro ( Supplementary Fig. S1A ). We next tested expression of the human MAGE-A consensus #1 and consensus #2 plasmids. We were able to detect robust expression of these plasmids by qPCR ( Supplementary Fig. S1B ). We were also able to detect expression of these plasmids by Western blot analysis, using either a Pan-MAGE-A antibody or a FLAG antibody that recognizes FLAG-tagged constructs ( Supplementary Fig. S1C ). The Pan-MAGE-A antibody was able to recognize the MAGE-A Consensus #2 vaccine construct, but not the Consensus #1 construct. As a control, we included 293T cells that were transfected with a human MAGE-A6 plasmid, which is slightly smaller than LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; STES, stomach and esophageal carcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma. the MAGE-A consensus #1 or consensus #2 plasmids by Western blot analysis ( Supplementary Fig. S1C ). This size shift is likely due to the addition of the IgE leader sequence.
Consensus mouse MAGE-A vaccine breaks tolerance to multiple MAGE-A isoforms in C57Bl/6 mice
To test the capacity of the mouse MAGE-A vaccine to break tolerance to multiple MAGE-A isoforms, we immunized C57Bl/6 mice with 25 mg of the mouse consensus MAGE-A vaccine three times at 2-week intervals and assessed cellular immune responses 1 week following the final vaccination (Fig. 3A) . We show, via IFNg ELISpot assay as well as intracellular cytokine staining of splenocytes that were stimulated with mouse native isoform-specific peptides, that our optimized designer vaccine is capable of inducing robust CD8 þ IFNg responses to all 6 isoforms predicted to cross-react with this vaccine (Fig. 3B-I) . Furthermore, nearly all of these antigen-specific CD8 þ splenocytes coexpressed the degranulation marker CD107a and the transcription factor T-bet, in addition to IFNg, indicating that these CD8 þ T cells have high cytolytic potential (Fig. 3J ). High levels of TNFa are also induced in CD8 þ T cells upon stimulation of splenocytes with isoform-specific peptides (Fig. 3K ). The immune response detected in C57Bl/6 mice was largely driven by CD8 þ T cells, as evidenced by the lower level of CD4 þ T-cell response for the individual MAGE-A isoforms ( Supplementary  Fig. S2 ). These data demonstrate that this optimized, synthetic MAGE-A vaccine is capable of breaking tolerance to multiple MAGE-A isoforms simultaneously in mice.
Because most of the immune responses observed were in peptide Pool 2, we ran IFNg ELISpots using the individual peptides that make up Pool 2. By running the individual peptides, we determined that the response in C57Bl/6 mice was dominated by a single epitope: MKVLQFFASINKTHP ( Supplementary  Fig. S3 ). This epitope contains both an 8-mer (VLQFFASI) and 9-mer (KVLQFFASI) that are predicted to have the highest MHC class I binding affinity (36.8 nmol/L and 20.5 nmol/L IC 50 , respectively) of all possible mouse MAGE-A epitopes, according to the IEDB NetMHCPan prediction program.
We next evaluated memory responses to the MAGE-A vaccine in C57Bl/6 mice. We immunized mice two times, and sacrificed the mice either one week after final dose or 50 days after final dose of vaccine ( Supplementary Fig. S4A ). The immune responses decreased over time, but were maintained into memory 50 days after the final immunization (Supplementary Fig. S4B ). Importantly, we were able to detect T cells that expressed IFNg, TNFa, and coexpressed IFNg/T-bet/ CD107a in response to antigen stimulation in the mice sacrificed 50 days post-final dose ( Supplementary Fig. S4C-S4E ).
Because of potential toxicity concerns related to MAGE-A3targeted TCR gene therapy, we closely examined MAGE-A DNA vaccine-immunized mice for adverse events. We immunized 5 mice three times at 2-week intervals, and monitored mice for a total of 9 months after the first immunization. We did not observe any apparent toxicity in these mice upon observation. Upon euthanization and dissection of these mice, we also did not observe any gross organ abnormalities. Upon closer pathologic examination of organs, we noted mild inflammation in the kidney, liver, pancreas, and spleen ( Supplementary Fig. S5A and  S5B) . A similar degree of inflammation was noted in age-matched control immunized mice, indicating that this pathology was likely not due to the MAGE-A vaccine itself. Importantly, no pathologic abnormalities were noted in the brain or heart.
Consensus MAGE-A vaccine breaks tolerance to multiple MAGE-A isoforms in CD-1 outbred mice
Because the inbred C57Bl/6 mice responded primarily to one immunodominant epitope, we next tested this consensus mouse MAGE-A vaccine in CD-1 outbred mice to determine whether it would generate cross-reactive immune responses in genetically diverse mice. We immunized 15 CD-1 outbred mice with 25 mg of the mouse consensus MAGE-A vaccine three times at 2-week intervals and assessed cellular immune responses one week following the final vaccination. We determined, by IFNg ELISpot, that the consensus mouse MAGE-A vaccine is immunogenic in CD-1 mice against peptides matched to the consensus vaccine sequence, and is capable of breaking tolerance to multiple MAGE-A isoforms simultaneously in the majority of the mice (Fig. 4A and B) . Despite the genetic diversity of these mice, the majority of animals generated immune responses against all 6 individual MAGE-A isoforms (Fig. 4B ).
Antitumor activity of MAGE-A vaccine in melanoma tumor models
To identify an appropriate model for a tumor challenge, we evaluated MAGE-A expression in a panel of mouse cell lines syngeneic to either C57Bl/6 or Balb/c strains of mice. We used Pan-MAGE-A qPCR primers that recognize MAGE-A isoforms A1, A2, A3, A5, A6, and A8 simultaneously. This analysis showed high expression of MAGE-A isoforms in the B16F10 and YUMM1.7 melanoma cell lines and the LLC and TC-1 lung cancer cell lines ( Supplementary Fig. S6A ). The highest expression was observed in the YUMM1.7 cell line, which is derived from a transgenic melanoma model expressing BrafV600E, and has both Pten and Cdkn2 knockout (34) . Therefore, we chose to test the MAGE-A in a similar autochthonous tumor model in which Braf V600E expression and PTEN loss are driven by Cre activation in melanocytes of the skin by tamoxifen induction (Tyr::CreER; Braf CA/þ ;Pten lox/lox mice; ref. 28) . We verified that autochthonous tumors from these mice express MAGE-A isoforms at the RNA level ( Supplementary Fig. S6B ). Upon induction with topical 4-OHT (tamoxifen), these mice develop melanoma with 100% penetrance. One week after 4-OHT induction, we began immunization with either a modified pVax control plasmid or the consensus mouse MAGE-A plasmid (Fig. 5A ). We observed that the mouse consensus MAGE-A vaccine was effective at significantly slowing tumor growth in this model, and prolonged mouse survival by a median of 50 days compared with the modified pVax control group (2-fold prolongation in survival, Fig. 5B and C). We sacrificed half of the mice in the study at day 50 to evaluate appearance and immune infiltration in melanoma tumors, as well as examine the immune response in the spleen. We found that the MAGE-A vaccine was able to decrease melanoma invasion depth in the skin (Fig. 5D and E) , as well as drive CD8 þ T cells to the tumor (Fig. 5F and G) . Furthermore, the Antitumor activity of MAGE-A vaccine in an autochthonous melanoma model. A, Tumor study outline. Tyr::CreER; BRAF Ca/þ ; Pten lox/lox transgenic mice were administered topical tamoxifen on their backs on day 0 to initiate melanoma formation. Mice were immunized with either control (pVax) or MAGE-A vaccine once weekly starting on day 7 for a total of 4 immunizations. Mice were monitored for tumor growth and survival. B, Tumor volume measurements over time for pVax control mice or MAGE-A-immunized mice. C, Mouse survival over time for pVax control mice or MAGE-A-immunized mice. Mice were euthanized according to the standard body condition score. D, Representative H&E images of tumors harvested from pVax control and MAGE-A-immunized mice that were sacrificed on day 50. E, Quantification of invasion depth in mm from H&E images of tumor tissue harvested from pVax or MAGE-A-immunized mice at day 50. F, Representative images of immunofluorescence staining of melanomas for CD8 (green) T cells and DAPI (blue). G, Quantification of images in (F), in terms of CD8 þ T cells per image. Image quantification was performed for three representative images per mouse. HPF, high-power field. H and I, Surface staining of tumor-infiltrating CD8 þ (H) and CD4 þ (I) T cells for CD44 and PD1 expression. For (B), N ¼ 11 mice for pVax control group and 16 mice for MAGE-A-immunized group. Eight mice from the MAGE-A group were sacrificed for immune analysis on day 50, and the remaining mice were followed for survival (C). Significance for tumor volume measurements over time was determined by multiple t tests for each time point. Significance for mouse survival was determined by the Gehan-Breslow-Wilcoxon test. Ã , P < 0.05; ÃÃ , P < 0.01; ÃÃÃ , P < 0.001; ÃÃÃÃ , P < 0.0001. Error bars, AE SEM. Scale bar, 100 mm for D. Scale bar, 50 mm for F.
CD4 þ and CD8 þ T cells in tumor tissues exhibited higher expression of CD44 and PD-1, markers of immune activation ( Fig. 5H and I). Tumor-bearing mice immunized with the MAGE-A vaccine also exhibited robust antigen-specific CD8 þ T-cell responses in the spleen, which persisted at least 22 days after the final immunization ( Supplementary Fig. S7A ). Additional aspects of the tumor microenvironment, such as blood vessel size and density, myeloid-derived suppressor cell infiltration and regulatory T-cell infiltration, were not impacted by the MAGE-A vaccine ( Supplementary Fig. S7B-S7F) .
We next tested the efficacy of our vaccine in the more aggressive, faster-growing subcutaneous YUMM1.7 tumor model ( Supplementary Fig. S8 ). We set up a tumor challenge study to evaluate the efficacy of the MAGE-A vaccine in this tumor model as well as to assess the dependence of any antitumor activity on CD8 T-cell-mediated immunity. We implanted mice with YUMM1.7 tumor cells, began immunization after palpable tumors formed on day 7, and treated mice with either an isotype control antibody or a CD8 depletion antibody ( Supplementary Fig. S8A ). We found that the MAGE-A vaccine had a significant antitumor impact in this model, which was lost upon depletion of CD8 T cells in the mice ( Supplementary Fig. S8B ). These results strongly support the potency of this MAGE-A vaccine for melanoma therapy. 
Immunogenicity and cross-reactivity of human MAGE-A consensus DNA vaccines in mice
We next tested the ability of the human versions of our MAGE-A DNA vaccines to generate cross-reactive immune responses in C57Bl/6 mice (Fig. 6A ). We immunized C57Bl/6 mice with 25 mg of the Human MAGE-A Consensus #1 vaccine or the Human MAGE-A Consensus #2 vaccine three times at 2-week intervals, and assessed cellular immune responses one week following the final immunization (Fig. 6A ). We observed that both vaccines are immunogenic and generate robust IFNg ELISpot responses to the vaccine-matched, consensus MAGE-A peptides ( Fig. 6B and D) . We also show that both vaccines generate cross-reactive responses towards all predicted human MAGE-A isoforms by IFNg ELISpot (Fig. 6C and E) . The MAGE-A Consensus #1 vaccine generates cross-reactive immune responses against MAGE-A2, MAGE-A3, MAGE-A6, and MAGE-A12. The MAGE-A Consensus #2 vaccine generates cross-reactive immune responses against MAGE-A1, MAGE-A4, and MAGE-A5.
Discussion
Previous clinical efforts to target the MAGE-A family member with immunization have focused on MAGE-A3 specifically, based on limited gene expression data showing high expression for this particular isoform in various solid tumors (11) . Here, we report data from TCGA showing that each member of the MAGE-A family, not just MAGE-A3, is highly expressed in human tumors (approximately 10%-30% of all human tumors for each isoform). In fact, based on TCGA data, 84% of melanoma patients express 1 or more isoforms that are targeted by the two Human MAGE-A consensus vaccines that we developed, indicating important clinical applicability for patients with melanoma. Furthermore, multiple MAGE-A family members are expressed within the same tumor, particularly so in patients with melanoma. These data provide further support for the development of a cross-reactive vaccine that can target multiple MAGE-A family members simultaneously.
The entire MAGE-A family is clustered on the X-chromosome; however, each family member is under independent transcriptional control (35) . The reason for this independent regulation is not clear, nor is our understanding of the individual regulation; however, this family of antigens is thought to be silenced by promoter methylation in normal human tissues (4, 36, 37) . This methylation is removed in tumor cells due to epigenetic reprogramming. While certain MAGE-A isoforms are suggested to have roles in cancer-promoting signaling pathways, it is not clear whether these isoforms are necessary for tumor progression (38) (39) (40) (41) . This suggests that tumors could escape immune pressure from a MAGE-targeted vaccine through downregulation of a particular MAGE isoform. However, this immune evasion becomes less probable when multiple MAGE-A family members are targeted simultaneously. Thus, a cross-reactive MAGE-A vaccine has a significant advantage over vaccines that target individual MAGE-A isoforms in preventing tumor immune escape.
The MAGE-A family of proteins may be unique in its ability to generate spontaneous T-cell responses in patients, indicating a potential lack of tolerance or more limited tolerance to this family of antigens (1, (5) (6) (7) (8) (9) (10) . While naturally occurring responses to MAGE-A family members do exist, they are still relatively rare, making the role of tolerance to this antigen unclear (42, 43) . In a small cohort of patients (5 patients), it was shown that there is expression of MAGE-A isoforms in medullary thymic epithelial cells, but that expression of each isoform was variable (44) . MAGE-A1 isoform expression was only detected in 1 of 5 patients, while MAGE-A3 and MAGE-A4 expression was detected in 4 of 5 patients (44) . These data indicate that targeting multiple MAGE-A isoforms may be advantageous for eliciting an immune response against select isoforms that may not be subject to central tolerance. More study needs to be performed in this regard in humans to better understand factors that affect tolerance to this family of antigens. One advantage of this design is that, by including diversity into the design of these antigens, these hotspots of dissimilarity are quite similar to neoepitopes. They would be expected to drive cross-reactive class II responses to these hotspots, generating improved ability to break tolerance. Indeed, using the mouse MAGE-A immunogen, we demonstrate that the consensus vaccine design strategy is effective at breaking tolerance to many mouse MAGE-A isoforms.
There are some toxicity concerns regarding MAGE-A3targeted TCR gene therapy. Two cellular CD8-based MAGE-A3 TCR therapies have been tested in the clinic. Unfortunately, in both clinical trials, patients experienced unexpected toxicity, which precluded further clinical development of these therapies. An affinity-enhanced HLA-A Ã 01-specific MAGE-A3 TCR therapy showed unexpected cardiovascular toxicity in the first 2 patients treated due to cross-reactivity of the TCR with peptide from the muscle-specific titin protein (15, 16) . A separate study used a high-avidity HLA-A Ã 0201-specific MAGE-A3 TCR, which showed unexpected neurologic toxicity in 3 of 9 patients, resulting in 2 unexpected deaths (45, 17) . This was likely due to cross-reactivity of the TCR with low levels of MAGE-A9/12 expression in neuronal cells of these patients. The toxicity correlated with the number of engineered T cells that were adoptively transferred, suggesting that lower levels of T cells or a lower affinity TCR may avoid this type of toxicity (45, 17) . Patients in this study received between 28-79 billion MAGE-specific T cells, in addition to one or more doses of IL2 (17) . Despite the fact that there was unprecedented toxicity, 5 of 9 patients did show clinical regression of their lesions after treatment, suggesting that CD8 þ T-cell therapy can be effective in generating an antitumor response against this antigen that can have clinical impact (45, 17) .
Despite this toxicity shown with the MAGE-A3 TCR therapy, MAGE-A4 TCR therapy was successfully performed in patients with esophageal cancer without significant toxicity (10) . Furthermore, MAGE-A3-targeted vaccine immunotherapy was safe in patients, despite induction of MAGE-A3-specific CD4 þ T cells and antibodies (12, 13) . One advantage of the DNA vaccine platform is that we were able to examine mice immunized with the cross-reactive mouse MAGE-A immunogen long-term, which is not possible with TCR-based gene therapy. We did not observe any apparent off-tumor toxicity in these mice. Further studies in larger organisms, such as non-human primates, can further address this important issue. The DNA vaccine targeting MAGE-A antigens described here elicits antitumor immunity while generating fewer MAGE-specific CD8 þ T cells compared with TCRbased gene therapy, decreasing the likelihood of off-tumor toxicity. In addition, because DNA vaccines induce natural antigen-specific immunity (not ex vivo affinity-enhanced), there is likely in vivo regulation of the immune response to prevent this type of autoimmune attack. Because MAGE-A antigens are also induced in inflammatory conditions such as wound healing, as well as in the placenta during pregnancy (46, 47) , careful consideration will be required when selecting patient populations to exclude from receiving this therapy (for instance, patients who intend to become pregnant or patients with the potential to develop chronic wounds).
Because of the evolving cancer immunotherapy landscape, it will be important to evaluate any new cancer vaccine strategies in the context of immune checkpoint blockade. It has been recently reported that MAGE-A expression correlates with resistance to CTLA-4 blockade in patients with melanoma (48) , indicating that this MAGE-A vaccine may be an effective therapy for patients who do not respond to ICB, or may be able to sensitize patients who are resistant to ICB. We reported that a DNA vaccine targeting the tumor-associated antigen TERT synergized with ICB in a mouse tumor model that is resistant to ICB alone (49) . In addition, this MAGE-A vaccine may synergize with epigenetic modifiers, which are known to upregulate expression of cancer germline antigens such as the MAGE family (50) . These combination strategies will be important to consider for future clinical applications.
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